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INTRODUCTION 
In 1994, following the discovery of the µ (MOP), δ (DOP), and κ (KOP) opioid receptor 
structures by molecular cloning, another similar receptor was identified and termed ORL1 
(opioid receptor like 1), a so-called ‘orphan’ receptor with an unknown ligand partner. 
Deorphanisation of ORL1 receptor proceeded parallelly by two research teams. Around the 
same time in 1995 both groups identified a heptadecapeptide as primary endogenous ligand for 
the orphan ORL1 receptor. The identical peptides were independently named as orphanin-FQ 
and nociceptin, respectively. These important studies are now considered pioneers of the so-
called ‘reverse pharmacology’ approach for drug discovery. The suggested nomenclature for 
the peptide involves the full name ‘nociceptin’ and the ‘N/OFQ’ abbreviation. The proper 
names for the receptor are ‘nociception receptor’ or ‘NOP receptor’ or ‘NOPr’, with the 
meaning of ‘Nociceptin Opioid Peptide receptor’. 
The NOP receptor belongs to the superfamily of G-protein coupled receptors (GPCRs) 
and to the family of rhodopsin-like receptors. Activation of the NOP receptor is mediated via 
Gi/Go proteins. Comparing the cDNAs of the NOP receptor, classical opioid receptors and other 
GPCRs, it is apparent that they contain a number of conserved amino acids and motifs. The 
TM2, TM3 and TM7 domains of opioid receptors show significant (70%) conservation. 
Intracellular loops (ICL) are also greatly homologous, particularly ICL3 (>80%), which plays 
a role in G protein activation.  
Regarding the tertiary structure of the opioid receptors, it has been found that the ligand 
binding pocket is located within the transmembrane helices in case of all four receptors. The 
message domains of endogenous opioid peptides (YGGF and FGGF) bind to this site.  
Although the structures of NOP and classical opioid receptors are closely related, the 
morphine-based general opioid antagonist naloxone is unable to inhibit the NOPr mediated 
effects. In addition, the NOP receptor binds opioid ligands very weakly at most. The 
tetrapeptide segment at the N-terminus of the endogenous opioid peptide ligands, called the 
message domain, is responsible for this high selectivity. According to the Schwyzer’s 
hypothesis, the message domain determines whether a peptide binds to classical opioid 
receptors or not, whereas the address domain determines the MOP, DOP or KOP receptor 
preference/selecivity of the peptide. This also explains why nociceptin cannot or very poorly 
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bind to classical opioid receptors, since its message domain differs from the opioid message 
domain.  
The NOP receptor and its ligand are present not only in the central nervous system but 
also in many peripheral organs and even in the immune system. The N/OFQ-NOP receptor 
system plays an important role in the cardiovascular and renal system. Moreover, it has been 
described that it inhibits gastrointestinal and airway motility. It also behaves as an 
immunomodulator, thus playing a role in the pathophysiology of sepsis and asthma.  
The NOP receptor is found in abundant quantities in the forebrain, the midbrain, the 
dorsal and ventral horns of the spinal cord and the brain stem. These are largely observed in 
pain-related brain regions, both ascending and descending pathways and they are also present 
in significant amounts in regions that mediate reward. 
In addition to pain, reward, stress and anxiety, the NOP receptor is involved in many 
other central processes such as learning and memory, emotional states, neuroendocrine 
regulation, food intake, and motor control.  
The effect of N/OFQ is mainly influenced by two factors: the dose and the route of 
administration. If N/OFQ is administered i.c.v. to rodents, it induces hyperalgesia and 
allodynia, and blocks the analgesic effect of MOP, DOP and KOP receptors. In the spinal cord 
N/OFQ has bidirectional effects, since it shows a pronociceptive effect in very low 
(femtomolar) concentrations, while in higher (nanomolar) dosage it has an analgesic effect. It 
is postulated that achievement of an antinociceptive effect through inhibition of the NOP 
receptor is only possible using i.c.v. administered NOP receptor antagonists.  
Since the discovery of morphine, a number of new opioid receptor drugs have been 
developed with the aim of eliminating the severe and unpleasant side effects of opioid 
pharmaceutics. Of the opioid receptors, the MOP receptor plays the most important role and 
new drugs have been developed for this receptor. These new ligands have more or less shown 
the side effects characteristic to morphine in human medicine. Some of these pharmaceuticals 
and their side effects are summarized in Table 1.  
Table 1: MOP receptor drugs and their common side effects. 
MOPr drugs Common side effects 
Codeine lightheadedness, dizziness, sedation, shortness of breath, nausea, 
vomiting, sweating, constipation  
Fentanyl fever, respiratory depression, nausea, vomiting, diaphoresis  
Levorphanol nausea, vomiting, altered mood, pruritus, flushing, difficulties in 
urination, constipation, biliary spasm  
Meperidine lightheadedness, dizziness, sedation, nausea, vomiting, sweating  
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Methadone euphoria, sedation, respiratory depression, miosis, bradycardia, 
physical dependence  
Morphine drowsiness, dizziness, sedation, fever, anxiety, confusion, tremor, 
diaphoresis, lethargy, feeling of warmth, respiratory depression, 
dry mouth, constipation, nausea, diarrhea, anorexia,  
abdominal pain, vomiting, chest pain, anemia, leukopenia, rash, 
peripheral eodema  
Oxycodone constipation, nausea, somnolence, dizziness, vomiting, pruritus, 
headache, dry mouth, asthenia, sweating, nausea, headache, 
pyrexia constipation  
Oxymorphone nausea, pyrexia, somnolence, vomiting, pruritus, headache, 
dizziness, constipation, confusion, diarrhea, insomnia, fatigue, 
decreased appetite, abdominal pain  
Tramadol nausea, constipation, dry mouth, somnolence, dizziness, vomiting  
Besides ligands acting on one of the receptors, mixed/bifunctional and bivalent opioid 
ligands were also developed. These ligands target more than one opioid receptors, which 
hopefully enables them to be more effective and helps reduce their side effects. Mixed opioid 
ligands currently on the market show somewhat milder adverse effects, though they are still 
frequently involved in drug abuse (Table 2).  
Table 2: Mixed Opioid drugs and their side effects. 
Mixed opioid 
agonist/antagonist 
drugs 
Receptor effect Common side effects 
Buprenorphine partial agonist at 
MOPr and NOPr, 
antagonist at KOPr 
and DOP 
headache, insomnia, pain, withdrawal, 
nausea, constipation, application site 
pruritus, vomiting, hyperhidrosis, 
dizziness, somnolence, dry mouth, 
rash, abuse  
Butorphanol  antagonist at MOPr, 
agonist at KOPr  
somnolence, dizziness, nausea, 
vomiting, abuse  
Nalbuphine  antagonist at MOPr 
agonist at KOPr  
sweaty, clammy, nausea, vomiting, 
dizziness, vertigo, dry mouth, 
headache, abuse  
Pentazocine  antagonist at MOPr 
agonist at KOP 
nausea, dizziness,lightheadedness, 
vomiting, euphoria, abuse  
 
Potential strategies include targeting receptor dimers with bifunctional or bivalent 
ligands. Bifunctional and bivalent drugs are not clearly distinguished from each other in the 
literature, and are sometimes used as synonyms. According to Dietis et al., bifunctional ligands 
are designed to be non-selective compounds that comprise two protein-binding drug moieties 
(with or without a spacer) in one chemical structure and act at two different therapeutic targets. 
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Bivalent ligands, on the other hand, are intended to be selective compounds, which composed 
of two distinct pharmacophores joined by a linker and usually have a larger molecular weight 
than bifunctional ligands. They are usually designed to bind to their two targets, which is not 
always achieved in practice. In the present thesis, the term bifunctional shall be used to refer 
to our newly synthesized ligands. 
One of the most preferred targets among opioid receptors is the MOP receptor. 
MOP/DOP, MOP/NOP, MOP/CCK2, MOP/NK1 and MOP/NTS receptor bivalent ligands 
have been developed to reduce side effects while maintaining the MOP receptor-mediated 
analgesic effects. 
In addition to these bivalents, MOP/NOP bivalent ligands are also widely researched. 
NOP receptor agonist and partial agonist ligands are both used for constructing bivalents of the 
MOP/NOP receptor.  
Among the NOP/MOP receptor agonists, the bifunctional ligand cebranopadol has been 
found to be effective even in the nanomolar range on the MOP, DOP, KOP and NOP receptors. 
In in vivo tests, it has proved to be an effective substance. This compound is currently in phase 
II and III clinical trials investigating the efficacy, safety and tolerability of the orally 
administered drug. 
Ac-RYYRIK-NH2 was in the focus of interest several times when MOP/NOP and other 
OP/NOP receptor bivalent ligands were developed. These bivalent ligands were designed to 
study the heterodimerization of opioid and NOP receptors, namely, the organization of the 
heterodimers; to develop new therapeutic agents, and to reduce morphine-related side effects.  
Kawano et al. used dermorphine besides Ac-RYYRIK-NH2 to form a MOP receptor 
agonist and NOP receptor antagonist ligand. Analogue 1, which they have created, binds to the 
MOP receptor with 200 times higher affinity than the starting ligands, and to the NOP receptor 
with 17 times higher affinity. 
Guillemyn et al. developed an effective MOP agonist and weak NOP antagonist peptide 
ligand 13a (H-Dmt-D-Arg-Aba-β-Ala-Arg-Tyr-Tyr-Arg-Ile-Lys-NH2). Intravenous 13a has a 
more prolonged effect than morphine. It had superior anti-allodynic and anti-hyperalgesic 
properties intrathecally than either morphine or Ac-RYYRIK-NH2. Overall, this ligand can 
already be effective at nanomolar concentrations and may be useful for both acute and 
neuropathic pain. 
Similarly to the previous research groups, Lagard et al. also used Ac-RYYRIK-NH2 to 
form their MOP/NOP receptor bivalent ligands. After acute and neuropathic pain tests, 
KGNOP1 (H-Dmt-D-Arg-Aba-bAla-Arg-Tyr-Tyr-Arg-Ile-Lys-NH2) proved to be the most 
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promising as its analgesic effect was more effective than that of even tramadol or morphine. In 
addition, its effect on respiratory depression was minimal.  
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AIMS OF THE STUDIES 
The N/OFQ-NOP receptor system is widely distributed in both the central and peripheral 
nervous system, the airways, the cardiovascular system, the urogenital and gastrointestinal 
tract, and the immune system. Since the N/OFQ-NOP receptor system is implicated in the 
regulation of numerous different biological functions in different ways, both NOP receptor 
agonists, antagonists and partial agonists are potentially useful tools for treating NOP receptor-
related disorders.  
In the present thesis 12 newly synthesized peptide ligands are described, 9 of which are 
N/OFQ variants and 3 of which OP/NOP receptor bifunctional ligands. 4 of the N/OFQ variants 
only contained elements of the N/OFQ sequence, while the remaining 5 also contained parts 
from the Ac-RYYRIK-NH2 sequence. 
 
The objectives of this study were set out as follows: 
 
  to characterize the binding affinity of 3 bifunctional ligands towards MOP, DOP, KOP 
and NOP receptors and the 9 fused N/OFQ hybrid peptides towards NOP receptor on rat and 
guinea pig brain membranes, 
  and to investigate the opioid receptors mediated G-protein activity in a functional 
[35S]GTPS binding assay, and to investigate the pharmacological activity on isolated MVD 
(mouse vas deferens), which contains all opioid receptors, including NOP receptor.  
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METHODS 
Competition radioligand binding experiments 
In competition binding experiments, the affinity (Ki) of an unlabeled compound is 
analysed by measuring radioligand specific binding in the presence of increasing 
concentrations of the unlabelled compound in question. The experimental data were analyzed 
and points were fitted with the professional curve fitting program GraphPad Prism 6.0 using 
non-linear regression. 
The tested ligands and their parent compounds (YGGF, YGGFL, nociceptin, Ac-
RYYRIK-NH2) were examined in rat and guinea pig brain membrane homogenates using 
highly MOP, DOP, KOP and NOP receptor selective ligands.  
The competition binding assays were performed in duplicates and repeated at least three 
times. 
 [35S]GTPγS binding experiments 
The [35S]GTPγS binding assay allows studying G protein activation. In this assays 
GDP→GTP exchange is measured using non-hydrolysable, radioactive [35S]GTPγS in the 
presence of the tested ligand in a given concentration. The measured radioactive signal 
corresponds to basal activity (100%) in the absence of an agonist. The [35S]GTPγS binding 
experiments also provided opportunity to study antagonism by MOP, DOP, KOP and NOP 
receptor selective ligands. The G-protein activity of opioid-nociceptin and nociceptin hybrid 
peptides were measured in rat and guinea pig brain membrane fractions.  
The maximal stimulation (Emax) of the G-proteins and the potency (EC50) of the tested 
ligands were calculated from the specifically bound [35S]GTPγS in the presence of the 
increasing concentrations of tested ligands.  
Isolated mouse vas deferens (MVD) bioassay 
This mouse vas deferens bioassay is used to assess the parameters of the ligands such as 
agonist potency and selectivity, which allow us to distinguish between full agonists, partial 
agonists and antagonists. 
To determine the equilibrium dissociation constant (Ke) of antagonists, the ‘single-dose’ 
method was applied.  
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SUMMARY OF THE RESULTS 
Bifunctional ligands 
  We concluded that the three bifunctional ligands bound to the DOP, KOP, NOP 
receptors even in a small concentration. BA55 had the highest affinity to the KOP and NOP 
receptors, BA61 to the NOP and DOP receptors, and BA62 to the DOP and KOP receptors.  
  The G-protein activation tests showed that both BA55 and BA62 stimulated the G-
proteins effectively, which was mediated by the DOP, KOP and NOP receptors. The 
stimulation of G-proteins by BA61 was weaker, and could be mediated through the DOP and 
NOP receptors, and, to a lesser extent, the MOP receptor. 
  Based on the results of the MVD bioassays, we deduced that all three ligands preferred 
the DOP and KOP receptors to the MOP and NOP receptors. According to the Ke values, BA61 
showed agonist activity on the DOP and NOP receptor, while BA62 was the strongest agonist 
of the KOP receptor.  
Nociceptin analogues and nociceptin-RYYRIK hybrid peptides 
  The radioligand competition binding assays showed that the ligands that showed 
greater NOP receptor affinity than the parent compounds were P1, P2, P4, P6 and P7.  
  In the G-protein activation tests, the P2 and P3 peptides showed full agonist effect on 
the NOP receptor. The remaining 7 peptides behaved as partial agonists. 
  In the MVD bioassay P1, P4, P5, P6 and P7 behaved as partial agonists. P4, P5 and 
P6 inhibited the effect of N/OFQ to a greater extent than the control JTC-801. 
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CONCLUSION 
Bivalent ligands acting on opioid receptors are an important area of research, since mixed 
or bifunctional compounds similar to bivalent ligands have already been used successfully in 
human medicine. In addition, compounds acting on the NOP receptor play a crucial role in the 
investigation of the N/OFQ-NOP system and its physiological effects, such as tolerance and 
dependence. 
We have synthesized multiple novel bifunctional ligand candidates, among which BA61 
proved to be promising as it was able to bind to the DOP receptor and weakly to the NOP 
receptor, even though the opioid message domain was at an unusual location.  
Among the 9 N/OFQ variants, P1, P4, P5, P6, and P7 showed the highest affinity towards 
the NOP receptor. In addition, P4, P5, P6, and P7 were efficient NOP receptor antagonists in 
the mouse vas deferens bioassay. These ligands carry the ‘Ac-RYYRIK’ motif at the N-
terminus, which suggests that ‘Ac-RYYRIK’ can work in place of the nociceptin message 
domain.  
Further in vitro and in vivo studies, such as rat tail-flick tests and gastrointestinal motility 
tests are needed to understand the exact pharmacology and possible clinical utility of the above 
mentioned peptides.  
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